| Active substance | Obinutuzumab |
| Holder | Roche |
| Status | Closed |
| Indication | In combination with chlorambucil for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 04/11/2015 |
Gazyvaro®
Last updated on 03/04/2024